The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction
ConclusionsThese results demonstrate the acceptable safety of the 6-g dose of CSL112 among AMI subjects with moderate stage 3 CKD and support inclusion of these patients in a phase 3 cardiovascular outcomes trial powered to assess efficacy.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Chronic Kidney Disease | Diabetes | Endocrinology | Heart | Heart Attack | Urology & Nephrology